Department of Laboratory Medicine, The Jikei University Daisan Hospital, Tokyo, Japan.
Department of Gastroenterology, Juntendo University School of Medicine, Tokyo, Japan.
Digestion. 2024;105(5):359-372. doi: 10.1159/000539788. Epub 2024 Jun 13.
This study evaluated the psychometric properties of the newly developed chronic constipation-therapeutic efficacy and satisfaction test (CC-TEST) among patients with chronic constipation.
Japanese patients with moderate or severe chronic constipation underwent a 4-week remedy. The baseline, 2-week, and 4-week assessments included the CC-TEST, Constipation Scoring System (CSS), Medical Outcome Study Short Form-8 Health Survey (SF-8), and Hospital Anxiety and Depression Scale (HADS). The CC-TEST comprises three domains: (1) symptoms; chronic constipation symptom severity (seven items), defecation status (five items), (2) impact for daily life; dissatisfaction with daily life level (DS; four items), and (3) therapeutic response; therapeutic efficacy measured by patients and medication compliance (four items).
Of 201 eligible patients at baseline, 110 completed the 4-week treatment and the survey responses. Cronbach's α values for the stool, defecation, and abdominal symptom subscales, as well as the total symptom score and DS subscale, showed good internal consistency reliability (0.72-0.80). Pearson's r for comparisons between corresponding items (CC-TEST symptoms with CSS, and CC-TEST DS with SF-8 physical and mental component summary scores) was significant. After 4 weeks, scores for symptoms, defecation status, and DS items/subscales notably decreased, with a significant effect size (p < 0.005, Cohen's d; 0.30-1.16). Statistically significant differences emerged between treatment responders and nonresponders using the three responder definitions, in changes in scores for most CC-TEST symptoms, defecation status, and DS items/subscales (p < 0.05).
CC-TEST demonstrates commendable reliability, convergent and known-group validity, and responsiveness to treatment effects. As a simple, comprehensive, and versatile patient-reported outcome measure, CC-TEST may be well suited for clinical trials and primary care of Japanese patients with chronic constipation.
本研究评估了新开发的慢性便秘治疗疗效和满意度测试(CC-TEST)在慢性便秘患者中的心理测量特性。
日本中重度慢性便秘患者接受 4 周的治疗。基线、2 周和 4 周评估包括 CC-TEST、便秘评分系统(CSS)、医疗结局研究简明健康调查量表(SF-8)和医院焦虑抑郁量表(HADS)。CC-TEST 包括三个领域:(1)症状;慢性便秘症状严重程度(7 项)、排便状态(5 项),(2)对日常生活的影响;对日常生活水平的不满(DS;4 项),(3)治疗反应;患者和药物依从性测量的治疗效果(4 项)。
在 201 名符合条件的基线患者中,110 名完成了 4 周的治疗和调查。粪便、排便和腹部症状子量表以及总症状评分和 DS 子量表的 Cronbach's α 值显示出良好的内部一致性可靠性(0.72-0.80)。相应项目(CC-TEST 症状与 CSS,CC-TEST DS 与 SF-8 身心成分综合评分)之间的 Pearson r 比较具有显著意义。4 周后,症状、排便状态和 DS 项目/子量表的评分显著下降,具有显著的效应量(p < 0.005,Cohen's d;0.30-1.16)。使用三种应答者定义,在大多数 CC-TEST 症状、排便状态和 DS 项目/子量表的评分变化方面,应答者和非应答者之间存在统计学显著差异(p < 0.05)。
CC-TEST 表现出良好的可靠性、收敛性和已知组有效性以及对治疗效果的反应性。作为一种简单、全面、多功能的患者报告结局测量工具,CC-TEST 可能非常适合日本慢性便秘患者的临床试验和初级保健。